GlassScriptPhysician profile
Adil Alavi
NPI 1649215161
$9,698.96
in general payments reported to CMS, 2019-2025
36 companies · $4,188 in 2025
The $4,188 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $132 · 2021: $1,632 · 2022: $305 · 2023: $1,123 · 2024: $1,843 · 2025: $4,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,917 · Consulting Fee: $2,130 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.18 |
| Consulting Fee | $2,130.00 |
| Education | $106.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,323.96 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $884.54 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $763.47 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $373.56 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $358.94 | 2019-2025 | Omnipod |
| Amgen INC. | $317.29 | 2022-2025 | Tepezza, Repatha, Repatha |
| Madrigal Pharmaceuticals | $281.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Corcept Therapeutics | $221.70 | 2022-2025 | Korlym |
| Horizon Therapeutics Plc | $180.13 | 2022-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.57 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Mannkind Corporation | $169.58 | 2019-2023 | Afrezza |
| Abbvie INC. | $154.76 | 2023-2025 | Synthroid |
| Recordati_rare_diseases_inc. | $142.35 | 2024-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $140.31 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $121.71 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $117.29 | 2024-2025 | |
| Sequel Med Tech, LLC | $99.06 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $84.77 | 2024-2025 | |
| Medtronic, INC. | $81.10 | 2023-2025 | Inpen Smart Insulin Delivery System |
| Ascendis Pharma Endocrinology INC | $64.93 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $62.03 | 2022-2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $59.79 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $57.88 | 2024-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $52.86 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $52.79 | 2025 | |
| Alexion Pharmaceuticals, INC. | $50.85 | 2025 | Strensiq |
| Ibsa Pharma INC. | $49.13 | 2019-2024 | Tirosint, Licart, Licart |
| Radius Health, INC. | $47.44 | 2024-2025 | Tymlos |
| Dexcom, INC. | $45.79 | 2019-2020 | |
| Beta Bionics, INC. | $32.82 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Soleno Therapeutics, INC. | $30.32 | 2025 | Vykat Xr |
| Kyowa Kirin, INC. | $27.91 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $25.65 | 2025 | |
| Rgh Enterprises LLC | $21.08 | 2025 | |
| Lifescan, INC. | $17.59 | 2019 | |
| Merck Sharp & Dohme LLC | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Alavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.